胰岛素瘤与食后低血糖和GLUT2/GCK/GLP-1RR特征性表达
Shinichiro Toyoda1,2, Sho Yoneda1,3, Kosuke Mukai1
1Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
The Journal of endocrinology
|February 16, 2026
概括
胰岛素瘤患者仅患有食后低血糖症,其葡萄糖载体2和GLP-1受体的表达更高. 这些标记物的表达减少与频繁的禁食低血糖症有关.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 代谢过程中的代谢.
背景情况:
- 低血糖是胰岛素瘤患者的主要症状.
- 之前的研究还没有基于低血糖类型的胰岛素瘤细胞的免疫组织化学差异.
研究的目的:
- 研究胰岛素瘤细胞中葡萄糖载体 (1-3),葡萄糖激酶和葡萄糖类-1受体表达的免疫组合化学差异.
- 为了将这些表达水平与临床低血糖现象类型 (禁食与食后) 相关联.
主要方法:
- 来自六个切除的胰腺样本的胰岛素瘤细胞的免疫组合化学分析.
- 评估葡萄糖载体1-3,葡萄糖激酶和葡萄糖类-1受体表达.
- 与临床低血糖概况 (禁食和食后) 的相关性.
主要成果:
- 一名仅患有食后低血糖症的患者表现出较高的葡萄糖载体2,葡萄糖激酶和GLP-1受体表达,相比之下,五名患有禁食和食后低血糖症的患者.
- 在所有患者中,葡萄糖载体1和3的表达是最小的或不存在的.
- 在患有频繁禁食低血糖症的患者中观察到葡萄糖酶和GLP-1受体的减少表达.
结论:
- 胰岛素瘤细胞中葡萄糖载体2的增加和降低的葡萄糖激酶和GLP-1受体表达可能与特定的低血糖特征有关.
- 这些发现提供了对胰岛素瘤不同临床表现背后的分子机制的见解.
更多相关视频
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.6K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.6K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Hypoglycemia and Glucagon
1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
Insulin Secretory Vesicles
7.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
7.0K
Diabetes Mellitus: Overview and Type I Subtype
5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K


